Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference
Kiniksa Pharmaceuticals (KNSA) will present at the Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020, at 8:50 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kiniksa Pharmaceuticals (KNSA) will present at the Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020, at 8:50 a.m. ET. A live webcast of the presentation can be accessed on the company's website, with a replay available for 14 days post-conference.
Kiniksa focuses on biopharmaceuticals, developing treatments for diseases with unmet needs. Its pipeline includes rilonacept, mavrilimumab, vixarelimab, and KPL-404, which target immunological pathways and aim to address underserved conditions.
Details
News Market Reaction – KNSA
The recorded move for KNSA in the trading session of this news was +9.87%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HAMILTON, Bermuda, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1st, 2020 at 8:50 a.m. Eastern Time.
A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference.
About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s product candidates, rilonacept, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These pipeline assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.
| Every Second Counts!™ Kiniksa Investor and Media Contact Mark Ragosa (781) 430-8289 mragosa@kiniksa.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.